Study of HX008 for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This is a single-arm, multicenter study to evaluate the efficacy and safety of HX008
injection in patients with BCG-unresponsive non-muscle invasive bladder cancer.